Author:
Moss Bernard,Carroll Miles W.,Wyatt Linda S.,Bennink Jack R.,Hirsch Vanessa M.,Goldstein Simoy,Elkins William R.,Fuerst Thomas R.,Lifson Jeffrey D.,Piatak M.,Restifo Nicholas P.,Overwijk Willem,Chamberlain Ronald,Rosenberg Steven A.,Sutter Gerd
Reference35 articles.
1. Andrew, M. E., Coupar, B. E. H., Ada, G. L. and Boyle, D. B., 1986, Cell-mediated immune response to influenza virus antigens expressed by vaccinia virus recombinants, Microb. Path. 1:443–452.
2. Bennink, J. R., Yewdell, J. W., Smith, J. W., Möller, C. and Moss, B., 1984, Recombinant vaccinia virus primes and stimulates influenza virus HA-specific CTL, Nature 311:578–579.
3. Bronte, V, Tsung, K., Rao, J. B., Chen, P. W., Wang, M., Rosenberg, S. A. and Restifo, N. P., 1995, IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases, J. Immunol. 154:5282–5292.
4. Buller, R. M., Chakrabarti, S., Cooper, J. A., Twardzik, D. R. and Moss, B., 1988, Deletion of the vaccinia virus growth factor gene reduces virus virulence, J. Virol. 62:866–877.
5. Buller, R. M. L., Smith, G. L., Cremer, K., Notkins, A. L. and Moss, B., 1985, Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype, Nature 317:813–815.
Cited by
98 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献